Danaher Q3 revenue ralies 8.5% to $6.55 billion

• Danaher (NYSE:DHR) reported third-quarter 2026 revenue of $6.554 billion, up 8.5% year over year, while net earnings from continuing operations increased 32.9% to $1.207 billion.
• Non-GAAP core revenue grew 3%, or 5.5% excluding respiratory-related revenue, while operating cash flow reached $1.9 billion and free cash flow totaled $1.6 billion.
• Danaher increased its full-year adjusted diluted EPS outlook to $8.57–$8.62, from $8.45–$8.60, and expects fourth-quarter core revenue growth of approximately 3%.

Danaher (NYSE:DHR) reported third-quarter 2026 revenue of $6.554 billion, up 8.5% year over year, supported by growth across its life sciences and diagnostics operations.

Net earnings from continuing operations increased to $1.207 billion from $908 million, while diluted earnings per share rose to $1.71 from $1.27.

Non-GAAP adjusted diluted earnings increased 11.5% to $2.11 per share, reflecting higher underlying profitability after adjustments for specified items.

Core revenue grew 3% on a non-GAAP basis, while growth excluding respiratory-related revenue reached 5.5%, indicating stronger performance outside that business category.

Looking ahead, Danaher raised its full-year adjusted diluted EPS guidance to $8.57–$8.62 from $8.45–$8.60, reflecting improved expectations for annual profitability.

Operating cash flow reached $1.9 billion during the quarter, while non-GAAP free cash flow totaled $1.6 billion, supporting the company's financial position.

For the fourth quarter, Danaher expects approximately 3% core revenue growth, with growth excluding respiratory revenue projected at 4%–5%.